Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.13 +0.69 (+1.32%)
Streaming Delayed Price Updated: 12:55 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
These companies have compelling long-term futures, but the coming decade could prove particularly exciting as each one comes into its own. 
Via The Motley Fool
News headline image
CRISPR Stock Surges in Recent Weeks: What's Going On? ↗
 
Via Benzinga
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
News headline image
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
10 Monster Stocks to Hold for the Next 10 Years ↗
Each of these 10 businesses offers a market-leading product or service within an industry that's set to explode. 
Via The Motley Fool
News headline image
Cathie Wood-Led Ark Launches Buffer ETFs For Its Flagship ARKK, Analyst Says It's Like Diet Soda — 50% Loss Protection, But There's A Catch ↗
Cathie Wood's Ark Investment Management has filed plans to launch four new exchange-traded funds designed to offer downside protection for investors in its flagship ARK Innovation ETF (BATS: ARKK),... 
Via Benzinga
Topics ETFs
News headline image
2 Beaten-Down Stocks With Massive Upside Potential ↗
Via The Motley Fool
News headline image
2 Growth Stocks to Buy Hand Over Fist in July ↗
These companies are poised to produce fireworks for your portfolio over the coming years. 
Via The Motley Fool
News headline image
44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy ↗
The 2025 TIME 100 Most Influential Companies list includes over 40 companies that investors can buy stock in. 
Via Benzinga
News headline image
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts ↗
Via The Motley Fool
News headline image
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering ↗
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
News headline image
The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
News headline image
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
News headline image
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
News headline image
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It ↗
Cathie Wood is bullish on biotech companies using gene sequencing, AI, and CRISPR tech to cure previously untreatable diseases. 
Via Benzinga
Topics Artificial Intelligence
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to bear more fruit. 
Via The Motley Fool
Topics Government World Trade
News headline image
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip ↗
Via The Motley Fool
Topics Economy
News headline image
5 Monster Stocks to Hold for the Next 10 Years ↗
These companies are just starting to realize the potential in up-and-coming fields, like AI and gene editing. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy? ↗
Via The Motley Fool
News headline image
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years ↗
Via The Motley Fool
News headline image
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders 
Via MarketBeat
News headline image
Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? ↗
Via The Motley Fool
News headline image
2 Biotech Stocks That Are Screaming Buys in May ↗
Via The Motley Fool
News headline image
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? ↗
The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline. 
Via The Motley Fool
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
The planets are lining up for these three stocks' underlying companies. 
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
News headline image
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst ↗
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025. 
Via Benzinga
News headline image
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
News headline image
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.